** Drug developer BridgeBio's BBIO.O shares rise 25% to $29.29 premarket

** The FDA on Friday approved BBIO's heart disease drug Attruby

** Co's oral drug was approved to treat a rare heart condition known as transthyretin amyloid cardiomyopathy that makes it hard for the heart to pump blood

** BBIO's drug is expected to compete with Pfizer's PFE.N Vyndaqel and Vyndamax

** As of last close, BBIO down ~42% YTD

(Reporting by Bhanvi Satija in Bengaluru)

((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))